Macrogenics (MGNX) Interest Expenses (2023 - 2026)
Macrogenics (MGNX) posted quarterly Interest Expenses of $5.5 million for Q1 2026, up 5909.89% year-over-year from $91000.0 in Q1 2025, and up 28.02% quarter-over-quarter from $4.3 million in Q4 2025.
Analysis
Macrogenics (MGNX) Interest Expenses (2023 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Interest Expenses for 15 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 5909.89% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $5.5 million (up 7391.78% YoY), while the FY2025 annual figure was $8.5 million, down 97.88% from the prior year.
- Interest Expenses advanced to $5.5 million in Q1 2026 per MGNX's latest filing, from $4.3 million in the prior quarter.
- Across five years, Interest Expenses topped out at $46.4 million in Q1 2024 and bottomed at -$24000.0 in Q4 2024.
- Historically, Interest Expenses has averaged $6.5 million across 5 years, with a median of $2.1 million in 2023.
- On a YoY basis, Interest Expenses climbed as much as 17900.0% in 2025 and fell as far as 99.8% in 2025.
- Macrogenics' Interest Expenses stood at $904000.0 in 2022, then jumped by 131.53% to $2.1 million in 2023, then sank by 101.15% to -$24000.0 in 2024, then surged by 17900.0% to $4.3 million in 2025, then increased by 28.02% to $5.5 million in 2026.
- Business Quant data shows MGNX's Interest Expenses at $5.5 million in Q1 2026, $4.3 million in Q4 2025, and $3.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Macrogenics | 276.32 Mn | 162.41 Mn | - | 4.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.40 Mn |
| Mar 31, 2026 | 4.89 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Sep 30, 2025 | 3.34 Mn |
| Jun 30, 2025 | 802,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | -24,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | 1.13 Mn |
| Jun 30, 2023 | 774,000.00 |
| Mar 31, 2023 | 656,000.00 |